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CLINICAL PRACTICE
INTRODUCTION
Gastroesophageal reflux disease (GERD) is a condi-
tion of reflux of gastric content into the esophagus, which
could create clinical symptoms.
Reflux can occur under normal conditions, usually
related to certain conditions, such as lying down after
meals, and during vomiting. If reflux occurs, the esopha-
gus would immediately contract to cleanse the lumen
from the refluxate, preventing prolonged contact between
the refluxate and the esophageal mucosa.1,2,3
According to the theory of balance (Shay theory),
refluxate is an aggressive factor, with acid as its main
component, while esophageal motility is a defensive fac-
tor, including lower esophageal sphincter tone.
Recurrent gastroesophageal reflux accompanied by
disturbed cleansing of the esophageal lumen creates an
inflammatory process in the esophageal mucosa. This
inflammation creates complaints in the patient in the form
of heart burn sensations and regurgitation.4,5,6
The incidence of GERD in Asia differs from that of
Western countries. In Japan, GERD is found at a rate of
approximately 2% each day. Complaints of heartburn
are usually brought up among those over 40 years of
age. Symptoms are usually mild. The most recent data
from the United States reported a weekly prevalence of
heartburn ranging from 18-42%.
The prevalence of esophagitis in an endoscopic study
in Indonesia on 127 patients with dyspepsia was 22.8%,
with a milder form in 90% of all cases. Similar data from
Japan demonstrated a prevalence rate for esophagitis
ranging between 1.29% and 9.96%, with a mild form in
70% of cases. Such low prevalence may be associated
to a difference in diet and the number of parietal cells
between Asian and Western populations.1,2,3,7
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PATHOPHYSIOLOGY
The development of abnormalities on the esophageal
mucosa due to reflux of gastric content, according to the
balance theory, may be classified into 2 types, as fol-
lows:
1. Defense of the Esophageal Mucosa
Defense of the esophageal mucosa may be classi-
fied into 3 levels, as follows:
1.1.Primary defense: anti-reflux barrier, which minimizes
the frequency and volume of reflux.
1.2.Secondary defense: lumen cleansing, which mini-
mizes contact between refluxate and body tissue
(esophageal epithel).
1.3.Tertiary defense: epithelial resistance, which mini-
mizes mucosal destruction during contact between
tissue and refluxate.
2. Aggressive factors associated with the potential
of refluxate
These factors may be classified into:
2.1.Gastric secretion
2.2.Pyloric competence
Defense of the esophageal mucosa can be classified
into 3 levels, as follows:
1. Pre-epithelial defense; the role of mucus and bicar-
bonate.
2. Epithelial defense: classified into physical barriers,
including cell membrane, junction, intercellular lipid,
and mucine. Functional components consist of cell
ability in controlling acid effect through epithelial
transport of sodium, hydrogen, and chloride ions, as
well as intracellular buffer through proteins and bi-
carbonate ions. In addition, epithelial ability to fix
damages through epithelial restitution and cell repli-
cation.
3. Post-epithelial defense, conducted through blood flow
in delivering oxygen, nutrients, and bicarbonate ions,
as well as eliminating hazardous substances such as
*This article has been published in Current Treatment in
Internal Medicine 2001
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are heartburn and regurgitation. In addition, atypical  
symptoms include non-cardiac chest pain, night time  
coughing and wheezing, hoarseness in the mornings  
(when waking), sore throat, and dental complaints. GERD  
symptoms often occur after meals, and often overlap  
with dyspepsia. Positive clinical symptoms without ab- 
normalities in 24-hour pH are associated with a condi- 
tion of transient lower esophageal sphincter relaxation  
(TLOSR). In this case, motility plays a more dominant  
role in producing symptoms.1,2,3,7,8  
 
DIAGNOSIS  
After typical clinical symptoms are found in an esoph- 
agitis reflux, there are several ways to establish a diag- 
nosis. Endoscopic examination is a way to determine  
esophagitis reflux (Table 1), even though 50-60% of en- 
doscopic results are negative. Histopathological exami- 
Figure 1. Balance theory of the esophageal mucosa 
 
carbon dioxide and hydrogen ions. Metabolic prod- 
ucts and dead cells are also eliminated through the  
blood. 
In addition to mucosal defense, the lower esophageal 
sphincter tone (LEST) also determines the development 
of reflux. Various endogenous components influence the 
LEST, particularly for the process of relaxation, such as 
secretin, glucagon, VIP, nicotinic acetylcholine, dopam- 
ine, hystamine, as well as PGE. 
Reduced LEST would facilitate the refluxate in re- 
peatedly entering the esophagus, usually accompanied  
by reduced esophageal peristalsis, causing prolonged  
contact between the refluxate and esophageal mucosa.  
 The role of the refluxate as an aggressive factor is  
particularly influenced by gastric acid. Lower gastric acid  
increases the aggressiveness of the refluxate. Thus, even  
though motility is satisfactory, and the LEST is normal,  
mucosal abnormality may still occur. From 24-hour pH  
monitoring, we found 62% of reflux cases with a pH of  
less than 4. If we consider the two factors stated above,  
the refluxate factor was a little more dominant compared  
to motility factors (AGA, 1998). This greatly determines  
the choice of treatment in GERD cases. 
Another clinical form of GERD is the non-erosive 
reflux disease (NERD). This abnormality is caused by 
hypersensitivity of esophageal mucosa to acid, associ- 
ated with increased perception of pain.1,2,3,4,5,6,8,9 
 
CLINICAL SIGNS AND SYMPTOMS 
Clinical symptoms will develop when there are ab- 
normalities in the esophageal mucosa. Typical symptoms 
nation will determine the presence of GERD according 
to the current classification, which is the Los Angeles 
classification (Table 1). 
Table 1. Los Angeles Classification 
Degree of abnormality Description 
A Changes in the mucosa, at least in the 
form of mucosal folds with a size of less 
than 5 mm 
B At  least  one or  more changes  in the 
mucosa/mucosal  fold,  with  a  size  of 
more than 5 mm, but without connection 
between the crest  of  one fold to the 
other 
C Presence of a connection between the 
peak of one mucosal fold to the other, 
without encircling the lumen 
D Circumferential lesion on the mucosa 
 
 
Tests that can be performed to establish GERD, as 
well as several types of mechanism and consequences 
of GERD can be found in Table 2.1,7 
Evaluation of the degree of endoscopic abnormality 
and evaluation of histological finding is crucial. Devel- 
opment of GERD into esophagitis, and then to Barret’s 
esophagus and carcinoma are conditions that need ad- 
equate management. 
During evaluation of LEST using manometry, most 
cases are found to be normal. In a study by Manan and 
Syafrudin on esophagitis cases, 60% of the results of 
LEST evaluation were found to be normal. This demon- 
strates that esophageal peristaltic function in maintain- 
ing lumen cleansing plays an important role.1,2,8  
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TREATMENT
GERD treatment can be classified into three types,
which are:
1. Supportive
2. Medication
3. Surgery
Supportive therapy is aimed at changing the patient’s
lifestyle, particularly avoiding types of foods that have
effect of LEST, and the patient’s activity.
Medications can be symptomatic and definitive. Short-
term use of antacids can reduce the patient’s complaints.
Reducing refluxate aggressiveness by controlling pH
is the treatment of choice. Medications that can be used
are anti-acids that function as proton-pump inhibitors,
with an optimal dose in the beginning of therapy, and
continued at half dosage at subsequent stages. The
choice of administering a single or a combination of drugs
should be known. Studies demonstrate that the degree
of esophageal abnormality greatly determines the therapy
of choice.
In the year 1996, AGA conducted a comparison of
treatment on various degrees of esophageal abnormality
(Table 3).1,10,11,12,13,14,15,16,17
Medications can be classified as symptomatic and
definitive treatment.
The use of antacids as gastric acid neutralizing agents
and sucralfate to increase tissue resistance are symp-
tomatic and supportive therapy.
Symptomatic therapy should only be administered for
a short period of time. Definitive therapy should be ad-
ministered for 4 weeks, and maintenance for another 4
weeks.
The most recent method of single-drug treatment is
the step down method, which recommends the use of
PPI with an initial dose of twice daily for 4 weeks, con-
tinued with half the initial dose for 4 weeks.
Clinical trials demonstrate different results for dif-
ferent PPIs. Among first generation PPIs, omeperazole
was proven to be more effective than lansoprazole, and
pantoperazole.
The most recent second generation PPI,
esomeperazole, an isomer of omeperazole, demonstrated
a far better result than first generation PPIs in clinical
trials.18
Evaluation of the result of treatment is conducted
clinically, and endoscopy is re-conducted to determine
clinical improvement objectively.
Even though it is still under debate, eradication of H.
pylori infection is considered necessary.19
The types of medicines that can be used to treat
GERD- reflux esophagitis is adjusted to the clinical con-
dition.1,13
The most recent approach for gastroesophageal re-
flux – reflux esophagitis is the step down method, using
one kind of proton pump inhibitor starting with an initial
Table 2. Examinations for GERD 
Test for reflux 
Upper gastrointestinal serial endoscopy 
Standard reflux test 
pH monitoring 
scintiscan using 99m Tc radionuclide 
Symptom-analysis testing 
Bernstein test 
pH monitoring 
 Acid suppression test 
Test to determine extent of esophageal damage 
 Serial barium meal 
 Endoscopy of the upper gastrointestinal tract 
 Esophageal biopsy 
 Measurement of difference in esophageal potential 
Test to analyse the pathogenesis of esophagitis 
 Acid clearance test* 
scintiscan using 99m Tc radionuclide* 
Esophageal manometry 
 Gastric acid analysis 
* = principally investigated procedures 
Step-Up Approach 
 
Step-Down Approach 
PPI (std dose) 
 
H2RA (anti reflux dose) 
      H2RA (std dose) 
ADVANTAGES ADVANTAGES 
Cost Saving 
Define lowest effective 
maintanance dose 
Record of long-term safety 
 
Q.D. dosing 
High rate of responders 
More complete relief 
Shorter time to symptom 
        control 
Shorter time to lesion      
        healing
 
DISADVANTAGES DISADVANTAGES 
B.I.D. DOSING 
High initial non responder 
Rate 
Incomplete relief
 
Higher cost 
Unsttled issues of l 
Long-term safety
 
 
Figure 2. The types of medicines that can be used to treat
GERD- reflux esophagitis
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dose of 1-2 times daily for 4 weeks, depending on the
drug, continued by half the initial dose for 4 weeks. If
there are clinical symptoms, short-term treatment is ad-
ministered (Genval, 1999).18
CONCLUSION
1. Gastroesophageal reflux disease is established from
clinical signs and symptoms.
2. Abnormalities may take the form of reflux esoph-
agitis to Barret’s esophagus. Similar clinical findings
are found in non-erosive gastroesophageal reflux
disease.
3. Diagnosis is established by means of endoscopy and
histopathology.
4. Treatment consists of supportive, medication, and
surgical treatment. Medications using the step down
method with proton pump inhibitors initiated with the
optimal dose continued by half the dose, with cost-
effectiveness in consideration.
5. Evaluation of treatment should be done regularly,
bearing in mind that this disease can advance into
carcinoma.
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Table 3. Efectiveness of therapies for GERD 
Class of Drugs How it works Eliminate 
symtoms 
Heal 
Esophagitis 
Manage or Prevent 
Complications 
Maintain 
remission 
Antacids Neutralize acid + 1 0 0 0 
H2 Blocker over-
the counter 
Mildly suppress acid + 1 0 0 0 
Promility Increase LES pressure; 
move acid from 
esophagus and stomach 
+2 +1 0 +1 
H2 Blockers 
Prescription 
Moderately suppress acid +2 +2 +1 +1 
H2 Blcckers + 
Promotility 
Moderately suppress 
acid; move acid from 
esophagus and stomach 
+3 +3 +1 +1 
High Dose H2 
Blockers 
Moderately suppress acid +3 +3 +2 +2 
Proton Pump 
Inhibitor 
Markedly suppress acid +4 +4 +3 +4 
Surgery Improve barrier between 
stomach and esophagus 
to prevent acid reflux 
+4 +4 +3 +4 
Note : Rating scale; 0 (no effect) to +4 nearly 100%(Adapted from ACG,1996) 
